Related references
Note: Only part of the references are listed.Neoadjuvant Chemotherapy/Gefitinib Followed by Concurrent Chemotherapy/Radiation Therapy/Gefitinib for Patients With Locally Advanced Squamous Carcinoma of the Head and Neck
John D. Hainsworth et al.
CANCER (2009)
Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature
Muhammad Wasif Saif et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells
Andres Lopez-Albaitero et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
ErbB receptors in the biology and pathology of the aerodigestive tract
Sarah Morgan et al.
EXPERIMENTAL CELL RESEARCH (2009)
Phase I Study of Lapatinib in Combination With Chemoradiation in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Kevin J. Harrington et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck
J. Simon W. Stewart et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms
Stephen Y. Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
Ezra E. W. Cohen et al.
LANCET ONCOLOGY (2009)
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Pasi A. Jaenne et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro
Na Zhang et al.
RADIOTHERAPY AND ONCOLOGY (2009)
High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes
Christian Giro et al.
RADIOTHERAPY AND ONCOLOGY (2009)
Molecular Target Approaches in Head and Neck Cancer: Epidermal Growth Factor Receptor and Beyond
Paul M. Harari et al.
SEMINARS IN RADIATION ONCOLOGY (2009)
Targeting EGFR in head and neck cancer: a decade of progress
Chris Boshoff et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2009)
Pim-1 Kinase Expression Predicts Radiation Response in Squamocellular Carcinoma of Head and Neck and Is under the Control of Epidermal Growth Factor Receptor
Katriina Peltola et al.
NEOPLASIA (2009)
A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck
Francesco Caponigro et al.
ANTI-CANCER DRUGS (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Head and neck cancer: Changing epidemiology, diagnosis, and treatment
Shanthi Marur et al.
MAYO CLINIC PROCEEDINGS (2008)
Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose
Christine H. Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Recent advances in head and neck cancer
Robert I. Haddad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
D. L. Wheeler et al.
ONCOGENE (2008)
Severe skin reaction secondary to concomitant radiotherapy plus cetuximab
Bernhard Berger et al.
RADIATION ONCOLOGY (2008)
Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma
Fabienne Thomas et al.
CLINICAL CANCER RESEARCH (2007)
The epidermal growth factor receptor: A role in repair of radiation-induced DNA damage
David J. Chen et al.
CLINICAL CANCER RESEARCH (2007)
Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer
Changhu Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck
Lars Bastholt et al.
RADIOTHERAPY AND ONCOLOGY (2007)
Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro
Kaisa Erjala et al.
RADIOTHERAPY AND ONCOLOGY (2007)
High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history
Bert H. O'Neil et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
R. Hitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I trial of vorinostat (V) in combination with pemetrexed (Pem) and cisplatin (CDDP) in patients with advanced cancer
L. Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes
Jing Li et al.
CLINICAL CANCER RESEARCH (2007)
Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group study
Lillian L. Siu et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab
Desmond Curran et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib
Mark Agulnik et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer
Stephane Temam et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients
Jing Li et al.
CANCER BIOLOGY & THERAPY (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
Jan B. Vermorken et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Integration of EGFR inhibitors with radiochemotherapy
Mukesh K. Nyati et al.
NATURE REVIEWS CANCER (2006)
Mechanisms of cutaneous toxicities to EGFR inhibitors
Mario E. Lacouture
NATURE REVIEWS CANCER (2006)
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting
John C. Sok et al.
CLINICAL CANCER RESEARCH (2006)
Signaling via ErbB2 and ErbB3 associates with resistance and Epidermal Growth Factor Receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells
Kaisa Erjala et al.
CLINICAL CANCER RESEARCH (2006)
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Jean Bourhis et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Xuewu Zhang et al.
CELL (2006)
Gefitinib: an adverse effects profile
Robert J. Cersosimo
EXPERT OPINION ON DRUG SAFETY (2006)
Effects of smoking on the pharmacokinetics of erlotinib
M Hamilton et al.
CLINICAL CANCER RESEARCH (2006)
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm
DG Pfister et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma
J Loeffler-Ragy et al.
EUROPEAN JOURNAL OF CANCER (2006)
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas
Christine H. Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Comparing antibody and small-molecule therapies for cancer
Kohzoh Imai et al.
NATURE REVIEWS CANCER (2006)
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
EEW Cohen et al.
CLINICAL CANCER RESEARCH (2005)
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study
B Burtness et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR
EEW Cohen et al.
CLINICAL CANCER RESEARCH (2005)
Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy
S Van Schaeybroeck et al.
CLINICAL CANCER RESEARCH (2005)
Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase
K Dittmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy
X León et al.
CLINICAL ONCOLOGY (2005)
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck
JW Lee et al.
CLINICAL CANCER RESEARCH (2005)
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
SQ Li et al.
CANCER CELL (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients
T Crombet et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The expanding role of systemic therapy in head and neck cancer
EEW Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
ER Wood et al.
CANCER RESEARCH (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors
ML Amador et al.
CANCER RESEARCH (2004)
Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines
LH Kalish et al.
CLINICAL CANCER RESEARCH (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients
R Bei et al.
JOURNAL OF PATHOLOGY (2004)
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
D Soulieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors
AW Burgess et al.
MOLECULAR CELL (2003)
TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells
A Gschwind et al.
EMBO JOURNAL (2003)
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck
EEW Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Cisplatin-induced activation of the EGF receptor
M Benhar et al.
ONCOGENE (2002)
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor
J Stamos et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma
J Woenckhaus et al.
JOURNAL OF PATHOLOGY (2002)
Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells
JN Contessa et al.
ONCOGENE (2002)
Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10
M Poetsch et al.
CANCER GENETICS AND CYTOGENETICS (2002)
Nuclear localization of EGF receptor and its potential new role as a transcription factor
SY Lin et al.
NATURE CELL BIOLOGY (2001)
Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer
F Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Cell signaling by receptor tyrosine kinases
J Schlessinger
CELL (2000)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
